News | May 11, 2026
Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
